SYN-TECH Chem. & Pharm. Co., Ltd.

TPEX:1777 Stock Report

Market Cap: NT$4.5b

SYN-TECH Chem. & Pharm Past Earnings Performance

Past criteria checks 2/6

SYN-TECH Chem. & Pharm has been growing earnings at an average annual rate of 13.3%, while the Pharmaceuticals industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 3.7% per year. SYN-TECH Chem. & Pharm's return on equity is 12.1%, and it has net margins of 24.4%.

Key information

13.3%

Earnings growth rate

2.4%

EPS growth rate

Pharmaceuticals Industry Growth18.5%
Revenue growth rate3.7%
Return on equity12.1%
Net Margin24.4%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

SYN-TECH Chem. & Pharm (GTSM:1777) Could Easily Take On More Debt

Mar 19
SYN-TECH Chem. & Pharm (GTSM:1777) Could Easily Take On More Debt

Here's What You Should Know About SYN-TECH Chem. & Pharm. Co., Ltd.'s (GTSM:1777) 4.6% Dividend Yield

Feb 26
Here's What You Should Know About SYN-TECH Chem. & Pharm. Co., Ltd.'s (GTSM:1777) 4.6% Dividend Yield

Declining Stock and Decent Financials: Is The Market Wrong About SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777)?

Feb 05
Declining Stock and Decent Financials: Is The Market Wrong About SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777)?

SYN-TECH Chem. & Pharm's (GTSM:1777) Shareholders Are Down 11% On Their Shares

Jan 10
SYN-TECH Chem. & Pharm's (GTSM:1777) Shareholders Are Down 11% On Their Shares

SYN-TECH Chem. & Pharm (GTSM:1777) Seems To Use Debt Rather Sparingly

Dec 19
SYN-TECH Chem. & Pharm (GTSM:1777) Seems To Use Debt Rather Sparingly

Here's What You Should Know About SYN-TECH Chem. & Pharm. Co., Ltd.'s (GTSM:1777) 4.6% Dividend Yield

Nov 28
Here's What You Should Know About SYN-TECH Chem. & Pharm. Co., Ltd.'s (GTSM:1777) 4.6% Dividend Yield

Revenue & Expenses Breakdown

How SYN-TECH Chem. & Pharm makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TPEX:1777 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 241,1172739038
31 Dec 231,1152519038
30 Sep 231,0912499339
30 Jun 231,0422709140
31 Mar 231,0583069040
31 Dec 229862959040
30 Sep 228833188239
30 Jun 227812307836
31 Mar 228541808539
31 Dec 218931778636
30 Sep 219721668633
30 Jun 211,0121758832
31 Mar 219841928027
31 Dec 209841878227
30 Sep 201,0281838426
30 Jun 201,0812058426
31 Mar 209871668327
31 Dec 199461597827
30 Sep 198821677628
30 Jun 197951397528
31 Mar 197881687428
31 Dec 187851547329
30 Sep 187291306727
30 Jun 186991116628
31 Mar 18701836628
31 Dec 17695606830
30 Sep 17737857335
30 Jun 177471007535
31 Mar 177421127835
31 Dec 167671587634
30 Sep 167581617331
30 Jun 167681896830
31 Mar 167271666228
31 Dec 156841566027
30 Sep 156511545826
30 Jun 156321385925
31 Mar 156241385825
31 Dec 146091285825
30 Sep 145791085524
30 Jun 14536845023
31 Mar 14528805023
31 Dec 13502784623
30 Sep 13469654424

Quality Earnings: 1777 has high quality earnings.

Growing Profit Margin: 1777's current net profit margins (24.4%) are lower than last year (29%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 1777's earnings have grown by 13.3% per year over the past 5 years.

Accelerating Growth: 1777's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 1777 had negative earnings growth (-10.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (2.8%).


Return on Equity

High ROE: 1777's Return on Equity (12.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.